Alexander L. Johnson

Alex Johnson brings broad international business experience in pharma and clinical diagnostics to CareDx. Prior to joining the company, Alex was Chief Operating Officer of BioGraph 55, a venture-backed immuno-oncology drug development company that uses advanced imaging analytics and machine learning to capture clinically relevant content from the tumor microenvironment. From 2009 to 2014 he was with Novartis, where he held roles at Novartis Diagnostics, a global provider of blood screening solutions, and Novartis M&A, based in Basel, Switzerland, where he led acquisitions in oncology and diagnostics. Prior to Novartis, Alex was with UBS Investment Bank in the Global Healthcare Group. Alex studied economics at Union College (N.Y.) and received his MBA in finance from Columbia Business School.